Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors
Phase I Dose Finding Study for GQ1001 in Patients with HER2-Positive Advanced Solid Tumors
HER2-positive Breast Cancer|HER2-positive Biliary Tract Cancer|HER2-Positive Salivary Gland Carcinomas|HER2-Positive Advanced Solid Tumor
DRUG: GQ1001
Dose Limiting Toxicities (DLTs)., Adverse events will be assessed using NCI CTCAE version 5.0 and will be evaluated by the investigator and the sponsor for the eligibility of DLT., End of Cycle 1 (21-day cycle)|Maximum Tolerated Dose (MTD) or Dose Recommended for Dose Expansion (DRDE), The SRC will also determine the MTD/DRDE based on the totality of data for all tested dose levels., After each cohort completes the DLT observation period (Day 1 to Day 21 after the first dose of study treatment) or has a DLT or becomes not DLT-evaluable
Incidence and Severity of Adverse Events (AEs), Safety and Tolerability of GQ1001, from baseline to 30 days after last dose|Number of Participants with Abnormal Laboratory Values, Safety and Tolerability of GQ1001, rom baseline through Cycle 8 (each cycle is 21 days) and up to 30 days from treatment discontinuationafter last dose|Area Under the Plasma Concentration Versus Time Curve (AUC) of GQ1001, through study completion, an average of 1 year|Peak Plasma Concentration of GQ1001 (Cmax), through study completion, an average of 1 year|Time at which the Cmax is Observed (Tmax), through study completion, an average of 1 year|Half Life of GQ1001 (T1/2), through study completion, an average of 1 year|Mean Residence Time of GQ1001 (MRT), through study completion, an average of 1 year|Volume of Distribution of GQ1001 (Vd), through study completion, an average of 1 year|Preliminary Efficacy of GQ1001 Evaluated using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and CT of MRI scans, through study completion, an average of 1 year|Immunogenicity, Anti-GQ1001 antibody/anti-therapeutic antibody, through study completion, an average of 1 year|Preliminary Efficacy, objective response rate (ORR), through study completion, an average of 1 year|Preliminary Efficacy, disease control rate (DCR), through study completion, an average of 1 year|Preliminary Efficacy, duration of response (DoR), through study completion, an average of 1 year|Preliminary Efficacy, progression-free survival (PFS), through study completion, an average of 1 year
Phase I Dose Finding Study for GQ1001 in Patients with HER2-Positive Advanced Solid Tumors